Evidence map›Paper›PMID 40261508›Full record

ReviewFunctional & integrative genomics2025

SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.

Hebatallah Ahmed Mohamed Moustafa, Walaa A El-Dakroury, Alaa Ashraf, Ahmed I Abulsoud, Shereen Saeid Elshaer, Nourhan M Abdelmaksoud, Nehal I Rizk, Sherif S Abdel Mageed, Mohamed Bakr Zaki, Reda M Mansour and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hebatallah Ahmed Mohamed MoustafaDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr, Cairo, 11829, Egypt.
Walaa A El-DakrouryDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.
Alaa AshrafDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr, Cairo, 11829, Egypt.
Ahmed I AbulsoudBiochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, 11231, Egypt.
Shereen Saeid ElshaerDepartment of Biochemistry, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, Egypt.
Nourhan M AbdelmaksoudDepartment of Biochemistry, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, Egypt.
Nehal I RizkDepartment of Biochemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, 11786, Egypt.
Sherif S Abdel MageedPharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.
Mohamed Bakr ZakiDepartment of Biochemistry, Faculty of Pharmacy, University of Sadat, Sadat, City, Menoufia, 32897, Egypt.
Reda M MansourZoology and Entomology Department, Faculty of Science, Helwan University, Helwan, Egypt.
Osama A MohammedDepartment of Pharmacology, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia.
Mai A Abd-ElmawlaDepartment of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Mustafa Ahmed Abdel-ReheimDepartment of Pharmacology, College of Pharmacy, Shaqra University, Shaqra, 11961, Saudi Arabia. m.ahmed@su.edu.sa.ORCID http://orcid.org/0000-0002-7728-0923
Ahmed S DoghishDepartment of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt. ahmed_doghish@azhar.edu.eg.ORCID http://orcid.org/0000-0002-0136-7096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, necessitating ongoing research to improve treatment outcomes and minimize adverse effects associated with chemotherapy. This article explores the role of genetic variations, particularly single nucleotide polymorphisms (SNPs), in influencing the efficacy and toxicity of chemotherapeutic agents used in BC treatment. It highlights the impact of polymorphisms in drug metabolism and transport genes, such as UDP-glucuronosyltransferase 1A1 (UGT1A1), carbonyl reductase 1 (CBR1), and ATP-binding cassette multidrug transporter (ABCB1) on the risk of adverse effects, including cardiotoxicity and hematological toxicities. By identifying specific SNPs associated with drug response and toxicity, this research underscores the potential for personalized medicine approaches to optimize treatment regimens, enhance therapeutic efficacy, and minimize side effects in BC patients. The findings advocate for the integration of genetic screening in clinical practice to improve patient outcomes and tailor chemotherapy based on individual genetic profiles.

Indexed as

Antineoplastic AgentsBreast NeoplasmsPolymorphism, Single NucleotideATP Binding Cassette Transporter, Subfamily BFemaleGlucuronosyltransferaseHumansPrecision MedicineUGT1A1 EnzymeABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BGlucuronosyltransferaseUGT1A1 EnzymeBreast cancerCardiac toxicityGastrointestinal toxicityHematological toxicityNeurotoxicitySingle nucleotide polymorphism

Identifiers

PMID40261508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.